Podcast appearances and mentions of sue desmond hellmann

The Bill & Melinda Gates Foundation, with an endowment of over $50 billion, is one of the largest and most influential philanthropic organizations in the world. With a focus on addressing global health, poverty, and education, its initiatives have led to the reduction of malaria mortality by 60% over the past two decades, the near eradication of polio, increased educational opportunities of millions of students, and improved sanitation conditions for millions of people in developing countries. For six years, oncologist Sue Desmond-Hellmann, MD, MPH was the CEO of this organization. Prior to that, she served as Chancellor of the University of California at San Francisco, as well as President of Product Development at Genentech, where she oversaw the development of Herceptin, Avastin, Rituxan, and other blockbuster cancer drugs that are now staples in the arsenal of many medical oncologists.The topics of our discussion in this episode are as varied as Dr. Desmond-Hellman's career. We discuss, among other things, how seeing the work of her pharmacist father encouraged her to pursue a career in medicine, how her early experiences treating HIV patients in Uganda spurred her to tackle global health challenges, how she discovered a passion for product development in the pharmaceutical industry, how she reconciles the ethical quandaries of developing medications that can cause serious adverse effects and that can sometimes cost hundreds of thousands of dollars per dose, what her mission while at the Gates Foundation was, and her perspectives on the role of artificial intelligence and human health and well-being, now that she has joined the board of directors of OpenAI, the company behind ChatGPT.In this episode, you will hear about: 2:50 - How working in her father's pharmacy led Dr. Desmond-Hellmann to a career in medicine4:56 - A brief summary of Dr. Desmond-Hellmann's multifaceted career trajectory15:36 - What the day to day work of pharmaceutical drug development looks like 18:30 - The challenging ethical concerns that surround drug approvals especially as it pertains to safety concerns23:44 - Dr. Desmond-Hellmann's experiences in Uganda that forever transformed her views on poverty 27:55 - The aims of the Gates Foundation 30:47 - How Dr. Desmond-Hellmann views her work both in the non-profit and the for-profit sectors 37:15 - Dr. Desmond-Hellmann's mission when she took on a leading role at The Gates Foundation 38:38 - How Dr. Desmond-Hellmann thinks about shaping the future of AI as she takes a seat on the board of OpenAI45:14 - Dr. Desmond-Hellmann's advice for medical trainees and clinicians on how to navigate the many opportunities available to them along their career pathDr. Sue Desmond-Hellmann can be found on Twitter/X @suedhellmann.Visit our website www.TheDoctorsArt.com where you can find transcripts of all episodes.If you enjoyed this episode, please subscribe, rate, and review our show, available for free on Spotify, Apple Podcasts, or wherever you get your podcasts. If you know of a doctor, patient, or anyone working in health care who would love to explore meaning in medicine with us on the show, feel free to leave a suggestion in the comments or send an email to info@thedoctorsart.com.Copyright The Doctor's Art Podcast 2024

Link to original articleWelcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: OpenAI: The Board Expands, published by Zvi on March 12, 2024 on LessWrong. It is largely over. The investigation into events has concluded, finding no wrongdoing anywhere. The board has added four new board members, including Sam Altman. There will still be further additions. Sam Altman now appears firmly back in control of OpenAI. None of the new board members have been previously mentioned on this blog, or known to me at all. They are mysteries with respect to AI. As far as I can tell, all three lack technical understanding of AI and have no known prior opinions or engagement on topics of AI, AGI and AI safety of any kind including existential risk. Microsoft and investors indeed so far have came away without a seat. They also, however, lack known strong bonds to Altman, so this is not obviously a board fully under his control if there were to be another crisis. They now have the gravitas the old board lacked. One could reasonably expect the new board to be concerned with 'AI Ethics' broadly construed in a way that could conflict with Altman, or with diversity, equity and inclusion. One must also remember that the public is very concerned about AI existential risk when the topic is brought up, so 'hire people with other expertise that have not looked at AI in detail yet' does not mean the new board members will dismiss such concerns, although it could also be that they were picked because they don't care. We will see. Prior to the report summary and board expansion announcements, The New York Times put out an article leaking potentially key information, in ways that looked like an advance leak from at least one former board member, claiming that Mira Murati and Ilya Sutskever were both major sources of information driving the board to fire Sam Altman, while not mentioning other concerns. Mira Murati has strongly denied these claims and has the publicly expressed confidence and thanks of Sam Altman. I continue to believe that my previous assessments of what happened were broadly accurate, with new events providing additional clarity. My assessments were centrally offered in OpenAI: The Battle of the Board, which outlines my view of what happened. Other information is also in OpenAI: Facts From a Weekend and OpenAI: Altman Returns. This post covers recent events, completing the story arc for now. There remain unanswered questions, in particular what will ultimately happen with Ilya Sutskever, and the views and actions of the new board members. We will wait and see. The New Board The important question, as I have said from the beginning, is: Who is the new board? We have the original three members, plus four more. Sam Altman is one very solid vote for Sam Altman. Who are the other three? We're announcing three new members to our Board of Directors as a first step towards our commitment to expansion: Dr. Sue Desmond-Hellmann, former CEO of the Bill and Melinda Gates Foundation, Nicole Seligman, former EVP and General Counsel at Sony Corporation and Fidji Simo, CEO and Chair of Instacart. Additionally, Sam Altman, CEO, will rejoin the OpenAI Board of Directors. Sue, Nicole and Fidji have experience in leading global organizations and navigating complex regulatory environments, including backgrounds in technology, nonprofit and board governance. They will work closely with current board members Adam D'Angelo, Larry Summers and Bret Taylor as well as Sam and OpenAI's senior management. Bret Taylor, Chair of the OpenAI board, stated, "I am excited to welcome Sue, Nicole, and Fidji to the OpenAI Board of Directors. Their experience and leadership will enable the Board to oversee OpenAI's growth, and to ensure that we pursue OpenAI's mission of ensuring artificial general intelligence benefits all of humanity." Dr. Sue Desmond-Hellmann is a non-profit leader and physician. ...

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: OpenAI: The Board Expands, published by Zvi on March 12, 2024 on LessWrong. It is largely over. The investigation into events has concluded, finding no wrongdoing anywhere. The board has added four new board members, including Sam Altman. There will still be further additions. Sam Altman now appears firmly back in control of OpenAI. None of the new board members have been previously mentioned on this blog, or known to me at all. They are mysteries with respect to AI. As far as I can tell, all three lack technical understanding of AI and have no known prior opinions or engagement on topics of AI, AGI and AI safety of any kind including existential risk. Microsoft and investors indeed so far have came away without a seat. They also, however, lack known strong bonds to Altman, so this is not obviously a board fully under his control if there were to be another crisis. They now have the gravitas the old board lacked. One could reasonably expect the new board to be concerned with 'AI Ethics' broadly construed in a way that could conflict with Altman, or with diversity, equity and inclusion. One must also remember that the public is very concerned about AI existential risk when the topic is brought up, so 'hire people with other expertise that have not looked at AI in detail yet' does not mean the new board members will dismiss such concerns, although it could also be that they were picked because they don't care. We will see. Prior to the report summary and board expansion announcements, The New York Times put out an article leaking potentially key information, in ways that looked like an advance leak from at least one former board member, claiming that Mira Murati and Ilya Sutskever were both major sources of information driving the board to fire Sam Altman, while not mentioning other concerns. Mira Murati has strongly denied these claims and has the publicly expressed confidence and thanks of Sam Altman. I continue to believe that my previous assessments of what happened were broadly accurate, with new events providing additional clarity. My assessments were centrally offered in OpenAI: The Battle of the Board, which outlines my view of what happened. Other information is also in OpenAI: Facts From a Weekend and OpenAI: Altman Returns. This post covers recent events, completing the story arc for now. There remain unanswered questions, in particular what will ultimately happen with Ilya Sutskever, and the views and actions of the new board members. We will wait and see. The New Board The important question, as I have said from the beginning, is: Who is the new board? We have the original three members, plus four more. Sam Altman is one very solid vote for Sam Altman. Who are the other three? We're announcing three new members to our Board of Directors as a first step towards our commitment to expansion: Dr. Sue Desmond-Hellmann, former CEO of the Bill and Melinda Gates Foundation, Nicole Seligman, former EVP and General Counsel at Sony Corporation and Fidji Simo, CEO and Chair of Instacart. Additionally, Sam Altman, CEO, will rejoin the OpenAI Board of Directors. Sue, Nicole and Fidji have experience in leading global organizations and navigating complex regulatory environments, including backgrounds in technology, nonprofit and board governance. They will work closely with current board members Adam D'Angelo, Larry Summers and Bret Taylor as well as Sam and OpenAI's senior management. Bret Taylor, Chair of the OpenAI board, stated, "I am excited to welcome Sue, Nicole, and Fidji to the OpenAI Board of Directors. Their experience and leadership will enable the Board to oversee OpenAI's growth, and to ensure that we pursue OpenAI's mission of ensuring artificial general intelligence benefits all of humanity." Dr. Sue Desmond-Hellmann is a non-profit leader and physician. ...

Link to original articleWelcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: What do we know about the AI knowledge and views, especially about existential risk, of the new OpenAI board members?, published by Zvi on March 11, 2024 on LessWrong. They have announced three new board members in addition to Altman, but we seem to know almost nothing about their views or knowledge on any AI-related subjects? What if anything do we know? From OpenAI: We're announcing three new members to our Board of Directors as a first step towards our commitment to expansion: Dr. Sue Desmond-Hellmann, former CEO of the Bill and Melinda Gates Foundation, Nicole Seligman, former EVP and General Counsel at Sony Corporation and Fidji Simo, CEO and Chair of Instacart. Additionally, Sam Altman, CEO, will rejoin the OpenAI Board of Directors. Sue, Nicole and Fidji have experience in leading global organizations and navigating complex regulatory environments, including backgrounds in technology, nonprofit and board governance. They will work closely with current board members Adam D'Angelo, Larry Summers and Bret Taylor as well as Sam and OpenAI's senior management. Bret Taylor, Chair of the OpenAI board, stated, "I am excited to welcome Sue, Nicole, and Fidji to the OpenAI Board of Directors. Their experience and leadership will enable the Board to oversee OpenAI's growth, and to ensure that we pursue OpenAI's mission of ensuring artificial general intelligence benefits all of humanity." Dr. Sue Desmond-Hellmann is a non-profit leader and physician. Dr. Desmond-Hellmann currently serves on the Boards of Pfizer and the President's Council of Advisors on Science and Technology. She previously was a Director at Proctor and Gamble, Meta (Facebook), and the Bill & Melinda Gates Medical Research institute. She served as the Chief Executive Officer of the Bill & Melinda Gates Foundation from 2014 to 2020. From 2009-2014 she was Professor and Chancellor of the University of California, San Francisco (UCSF), the first woman to hold the position. She also previously served as President of Product Development at Genentech, where she played a leadership role in the development of the first gene-targeted cancer drugs. Nicole Seligman is a globally recognized corporate and civic leader and lawyer. She currently serves on three public company corporate boards - Paramount Global, MeiraGTx Holdings PLC, and Intuitive Machines, Inc. Seligman held several senior leadership positions at Sony entities, including EVP and General Counsel at Sony Corporation, where she oversaw functions including global legal and compliance matters. She also served as President of Sony Entertainment, Inc., and simultaneously served as President of Sony Corporation of America. Seligman also currently holds nonprofit leadership roles at the Schwarzman Animal Medical Center and The Doe Fund in New York City. Previously, Seligman was a partner in the litigation practice at Williams & Connolly LLP in Washington, D.C., working on complex civil and criminal matters and counseling a wide range of clients, including President William Jefferson Clinton and Hillary Clinton. She served as a law clerk to Justice Thurgood Marshall on the Supreme Court of the United States. Fidji Simo is a consumer technology industry veteran, having spent more than 15 years leading the operations, strategy and product development for some of the world's leading businesses. She is the Chief Executive Officer and Chair of Instacart. She also serves as a member of the Board of Directors at Shopify. Prior to joining Instacart, Simo was Vice President and Head of the Facebook App. Over the last decade at Facebook, she oversaw the Facebook App, including News Feed, Stories, Groups, Video, Marketplace, Gaming, News, Dating, Ads and more. Simo founded the Metrodora Institute, a multidisciplinary medical clinic and research foundation dedicated to t...

OpenAI anunció a los miembros de su nueva mesa directiva, entre los que se encuentra su CEO, Sam Altman. Otros miembros incluyen a Sue Desmond-Hellmann, Nicole Seligman y Fidji Simo, quienes vienen de la fundación Bill y Melinda Gates, Sony o Instacart, respectivamente. Estos nombramientos vienen después de varias críticas sobre la falta de representación en esta sección, lo cual se podría reflejar en sesgos en el desarrollo de Inteligencia Artificial.Para esta y más noticias, escucha el podcast de Noticias de Tecnología ExpressDisponible en Spotify y en Apple Podcasts

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: What do we know about the AI knowledge and views, especially about existential risk, of the new OpenAI board members?, published by Zvi on March 11, 2024 on LessWrong. They have announced three new board members in addition to Altman, but we seem to know almost nothing about their views or knowledge on any AI-related subjects? What if anything do we know? From OpenAI: We're announcing three new members to our Board of Directors as a first step towards our commitment to expansion: Dr. Sue Desmond-Hellmann, former CEO of the Bill and Melinda Gates Foundation, Nicole Seligman, former EVP and General Counsel at Sony Corporation and Fidji Simo, CEO and Chair of Instacart. Additionally, Sam Altman, CEO, will rejoin the OpenAI Board of Directors. Sue, Nicole and Fidji have experience in leading global organizations and navigating complex regulatory environments, including backgrounds in technology, nonprofit and board governance. They will work closely with current board members Adam D'Angelo, Larry Summers and Bret Taylor as well as Sam and OpenAI's senior management. Bret Taylor, Chair of the OpenAI board, stated, "I am excited to welcome Sue, Nicole, and Fidji to the OpenAI Board of Directors. Their experience and leadership will enable the Board to oversee OpenAI's growth, and to ensure that we pursue OpenAI's mission of ensuring artificial general intelligence benefits all of humanity." Dr. Sue Desmond-Hellmann is a non-profit leader and physician. Dr. Desmond-Hellmann currently serves on the Boards of Pfizer and the President's Council of Advisors on Science and Technology. She previously was a Director at Proctor and Gamble, Meta (Facebook), and the Bill & Melinda Gates Medical Research institute. She served as the Chief Executive Officer of the Bill & Melinda Gates Foundation from 2014 to 2020. From 2009-2014 she was Professor and Chancellor of the University of California, San Francisco (UCSF), the first woman to hold the position. She also previously served as President of Product Development at Genentech, where she played a leadership role in the development of the first gene-targeted cancer drugs. Nicole Seligman is a globally recognized corporate and civic leader and lawyer. She currently serves on three public company corporate boards - Paramount Global, MeiraGTx Holdings PLC, and Intuitive Machines, Inc. Seligman held several senior leadership positions at Sony entities, including EVP and General Counsel at Sony Corporation, where she oversaw functions including global legal and compliance matters. She also served as President of Sony Entertainment, Inc., and simultaneously served as President of Sony Corporation of America. Seligman also currently holds nonprofit leadership roles at the Schwarzman Animal Medical Center and The Doe Fund in New York City. Previously, Seligman was a partner in the litigation practice at Williams & Connolly LLP in Washington, D.C., working on complex civil and criminal matters and counseling a wide range of clients, including President William Jefferson Clinton and Hillary Clinton. She served as a law clerk to Justice Thurgood Marshall on the Supreme Court of the United States. Fidji Simo is a consumer technology industry veteran, having spent more than 15 years leading the operations, strategy and product development for some of the world's leading businesses. She is the Chief Executive Officer and Chair of Instacart. She also serves as a member of the Board of Directors at Shopify. Prior to joining Instacart, Simo was Vice President and Head of the Facebook App. Over the last decade at Facebook, she oversaw the Facebook App, including News Feed, Stories, Groups, Video, Marketplace, Gaming, News, Dating, Ads and more. Simo founded the Metrodora Institute, a multidisciplinary medical clinic and research foundation dedicated to t...

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: OpenAI announces new members to board of directors, published by Will Howard on March 10, 2024 on The Effective Altruism Forum. From the linked article: We're announcing three new members to our Board of Directors as a first step towards our commitment to expansion: Dr. Sue Desmond-Hellmann, former CEO of the Bill and Melinda Gates Foundation, Nicole Seligman, former EVP and General Counsel at Sony Corporation and Fidji Simo, CEO and Chair of Instacart. Additionally, Sam Altman, CEO, will rejoin the OpenAI Board of Directors. ... Dr. Sue Desmond-Hellmann is a non-profit leader and physician. Dr. Desmond-Hellmann currently serves on the Boards of Pfizer and the President's Council of Advisors on Science and Technology. She previously was a Director at Proctor and Gamble, Meta (Facebook), and the Bill & Melinda Gates Medical Research institute. She served as the Chief Executive Officer of the Bill & Melinda Gates Foundation from 2014 to 2020. From 2009-2014 she was Professor and Chancellor of the University of California, San Francisco (UCSF), the first woman to hold the position. She also previously served as President of Product Development at Genentech, where she played a leadership role in the development of the first gene-targeted cancer drugs. ... Nicole Seligman is a globally recognized corporate and civic leader and lawyer. She currently serves on three public company corporate boards - Paramount Global, MeiraGTx Holdings PLC, and Intuitive Machines, Inc. Seligman held several senior leadership positions at Sony entities, including EVP and General Counsel at Sony Corporation, where she oversaw functions including global legal and compliance matters. She also served as President of Sony Entertainment, Inc., and simultaneously served as President of Sony Corporation of America. Seligman also currently holds nonprofit leadership roles at the Schwarzman Animal Medical Center and The Doe Fund in New York City. Previously, Seligman was a partner in the litigation practice at Williams & Connolly LLP in Washington, D.C., working on complex civil and criminal matters and counseling a wide range of clients, including President William Jefferson Clinton and Hillary Clinton. She served as a law clerk to Justice Thurgood Marshall on the Supreme Court of the United States. ... Fidji Simo is a consumer technology industry veteran, having spent more than 15 years leading the operations, strategy and product development for some of the world's leading businesses. She is the Chief Executive Officer and Chair of Instacart. She also serves as a member of the Board of Directors at Shopify. Prior to joining Instacart, Simo was Vice President and Head of the Facebook App. Over the last decade at Facebook, she oversaw the Facebook App, including News Feed, Stories, Groups, Video, Marketplace, Gaming, News, Dating, Ads and more. Simo founded the Metrodora Institute, a multidisciplinary medical clinic and research foundation dedicated to the care and cure of neuroimmune axis disorders and serves as President of the Metrodora Foundation. It looks like none of them have a significant EA connection, although Sue Desmond-Hellmann has said some positive things about effective altruism at least. Thanks for listening. To help us out with The Nonlinear Library or to learn more, please visit nonlinear.org

In this episode, Dr. Sue Desmond-Hellmann, Member of President Biden's Council of Advisors on Science and Technology and former CEO of the Bill & Melinda Gates Foundation, Mike Huckman, Global Practice Leader of Executive Communications at Real Chemistry, and Jim Weiss, Founder and Chairman at Real Chemistry, discuss the importance of vaccination, the evolution of cancer treatments and the challenges of clinical trials. They also highlight the need for diverse representation in clinical trials, the implications of the Inflation Reduction Act on the pharmaceutical industry and the influence of science in public health and policymaking.

This podcast is a commentary and does not contain any copyrighted material of the reference source. We strongly recommend accessing/buying the reference source at the same time. ■Reference Source https://www.ted.com/talks/sue_desmond_hellmann_a_smarter_more_precise_way_to_think_about_public_health ■Post on this topic (You can get FREE learning materials!) https://englist.me/106-academic-words-reference-from-sue-desmond-hellmann-a-smarter-more-precise-way-to-think-about-public-health-ted-talk/ ■Youtube Video https://youtu.be/aGmNTfDz0j8 (All Words) https://youtu.be/j92SqokKxVA (Advanced Words) https://youtu.be/p-i3UFDbA0g (Quick Look) ■Top Page for Further Materials https://englist.me/ ■SNS (Please follow!)

Dr. Sue Desmond-Hellmann is an American icon - a physician-scientist who led the development of the first gene-targeted drug for treating breast cancer, former CEO of the Bill & Melinda Gates Foundation and Chancellor of UCSF, and esteemed board member. Sue shares how her purpose and personal values shaped her career.  Priceless.

Sue Desmond-Hellmann on becoming a physician-scientist and biotech industry leader.

051: What a fabulous talk was this. Thank you Anthony and John for such a humble and authentic discussion. I am so honored to have you both in my network as you are wonderful ambassadors for our profession. Anthony Carthew is a career professional with more than 25 years experience in PA & EA roles across government, corporate and entertainment industries. He joined the Sydney Opera House in 2006, and is currently Executive Assistant to the Chief Executive Officer Louise Herron, as well as the Head of Protocol - responsible for overseeing the arrangements for the Opera House's many visiting dignitaries and VIPs, including heads of state and members of royal families from around the globe. Anthony manages a team of Executive Assistants, and heads up the Sydney Opera House Pride network, to help promote diversity and inclusion at the Opera House for its staff, partners and visitors. His past roles include senior EA roles at David Jones (Australia's leading department store), the Australian Federation of AIDS Organisations and the Sydney Symphony Orchestra, amongst others. In 2018, Anthony was awarded EA of the Year Australasia (Executive PA Media), has spoken at many conferences and events in support of the EA profession, and is a highly-regarded mentor for aspiring PAs and EAs. John Shaw is a familiar face on my podcast and I am grateful he agreed to be part of this discussion as well. After 13 years of providing administrative support to award-winning recording artists and celebrities, John left the entertainment industry to broaden his knowledge and skills, and hone his talent further with a move into management consulting. He eventually returned to the world of entertainment, supporting the head of marketing of three major television networks, but John still felt he had something bigger to offer to the world. He found the opportunity he'd been looking for to make a bigger impact as part of his career, when he was hired in 2014 by Bill & Melinda Gates Foundation CEO, Sue Desmond-Hellmann, to be her executive assistant. He now works as Executive Business Administrator to the Board of Directors for Microsoft. When John's not at work, you can find him with his family and his beloved dogs. Here is the book link we talked about in this episode. I have this book as well and read it probably 100 times already: https://www.amazon.de/Hit-Refresh-Rediscover-Microsofts-Everyone-ebook/dp/B01HOT5SQA Enjoy this episode. Much love, Diana x

“Understanding who drives decision making in a community, understanding who people believe and then working with them in a respectful way, will be the differentiator for science.” — Dr. Sue Desmond-Hellmann. We are incredibly pleased to announce today's guest: Dr. Sue Desmond-Hellmann! The former CEO and Senior Advisor to the Bill & Melinda Gates Foundation and current board member of Pfizer. Throughout her 30+ year career, Dr. Sue Desmond-Hellmann has always been dedicated to improving the human condition with her knowledge and determination. Most recently she has made strides in public health, climate change and changing the conversation around science. Today's conversation focused around:  Some of the biggest influencers in her life Her journey of becoming an oncologist  What circumstances get her to flow states  Her vision of having eyes on the prize  Having a sense of purpose and mission  The importance of having a diverse and strong team that you can rely on  Wanting to change the communication around science to regain credibility  Educating people on public health and climate change  How you can expose your children to science from an early stage  And her admiration for Dr. Anthony Fauci!  After stepping down as the CEO from the Bill & Melinda Gates Foundation she has been playing several different roles:  Senior Advisor and board member of the Bill & Melinda Gates Medical Research Institute. Working with nonprofit organizations that are looking at the future of science in the US and the communication surrounding it Teaching at UC San Francisco and UC Berkeley  Product development advisor for different organizations   Current board member of Pfizer    *Listener Note: when the episode was recorded, the vaccines for Covid had not been approved by the FDA yet. Be sure to follow Sue on Instagram, Twitter and Facebook and connect with her on LinkedIn. Learn more about her work with Pfizer here.  Connect with John on Facebook, Instagram and Twitter. To delve more into health, happiness, breath and well-being, check out johntukums.com; or better yet, sign up for the newsletter so the best content related to breath and high performance comes straight to you. If this podcast brings you happiness, we'd be so grateful if you shared that with others. We appreciate everyone who takes 60 seconds to leave an honest rating & review on Apple Podcasts/iTunes or wherever you listen. Until next week; take in a deep breath to find your Happiness Oxygen.

Sue Desmond-Hellmann wrapped up a six-year tenure as CEO of the Gates Foundation this summer, where she sat at the center of the world’s largest philanthropic effort. Beyond her time there Sue was the chancellor of UC San Francisco, a division President at Genentech, and one of the world’s foremost oncology researchers – building a leadership profile that’s almost without rival. With her down to earth approach to leadership, the way she engages with people on her team, and how she builds team - there is a lot to learn from Sue on how to lead in all sectors and the common playbook she brings to each of those roles.

Sue Desmond-Hellmann wrapped up a six-year tenure as CEO of the Gates Foundation this summer, where she sat at the center of the world’s largest philanthropic effort. Beyond her time there Sue was the chancellor of UC San Francisco, a division President at Genentech, and one of the world’s foremost oncology researchers – building a leadership profile that’s almost without rival. With her down to earth approach to leadership, the way she engages with people on her team, and how she builds team - there is a lot to learn from Sue on how to lead in all sectors and the common playbook she brings to each of those roles.

Over the next several weeks Distillations will be talking to people who have special insight into the coronavirus crisis—biomedical researchers, physicians, public health experts, and historians.  In this episode we speak with Sue Desmond-Hellmann, an oncologist who worked with HIV patients in San Francisco in the 1980s during the HIV/AIDS epidemic. She was also the CEO of the Bill and Melinda Gates Foundation up until December 2019. Desmond-Hellmann tells us about her experiences working as a doctor during the HIV/AIDS epidemic and as a CEO of the Gates Foundation during the Ebola pandemic. She also discusses what we learned from HIV and Ebola that can help us in fighting COVID-19.  Credits Hosts: Alexis Pedrick and Elisabeth Berry Drago Senior Producer: Mariel Carr Producer: Rigoberto Hernandez Researcher: Lisa Grissom Image: by Krista Kennell/Fortune Most Powerful Women Summit.

Sue Desmond-Hellmann, former CEO, Bill & Melinda Gates Foundation; former Chancellor, UCSF; former President of Product Development, Genentech From serving as a frontline physician treating HIV patients in Uganda, to overseeing new therapies for a leading biopharma company, to running a renowned health sciences university, to heading the world's largest philanthropy – Sue Desmond-Hellmann has seen it all. It's little surprise, then, that when she surveys the current pandemic she sees possible solutions across a range of areas. Her conversation with Mike Milken covers broad topics including how to build a durable and effective public health infrastructure as well as deeply specific issues such as whether interleukin-6 inhibitors might be able to prevent the eventual cause of most COVID-19 fatalities – the phenomenon known as cytokine storms. She also points to signs that make her hopeful, including a major consortium launched at UCSF: “This is such a good example of a multi-lab, multi-investigator scientific collaboration where people are just going as fast as they can together, putting competition to the side.”

On this week’s Tech Nation, Moira speaks with Dr. Sue Desmond-Hellmann, the CEO of The Bill & Melinda Gates Foundation, and Dr. Penny Heaton, CEO of The Bill & Melinda Gates Medical Research Institute, also called Gates MRI. Then scientist-entrepreneur Dr. Jake Glanville, co-founder and Chief Scientific Officer of Distributed Bio, talks about developing a universal flu vaccine

On this week’s Tech Nation, Moira speaks with Dr. Sue Desmond-Hellmann, the CEO of The Bill & Melinda Gates Foundation, and Dr. Penny Heaton, CEO of The Bill & Melinda Gates Medical Research Institute, also called Gates MRI. Then scientist-entrepreneur Dr. Jake Glanville, co-founder and Chief Scientific Officer of Distributed Bio, talks about developing a universal flu vaccine.

Washington is quiet this week, ahead of the Fourth of July holiday and with Congress on recess. So we're featuring excerpts from two classic conversations: doctor-turned-venture capitalist Bijan Salehizadeh on how he invests in health care and why he passed on Theranos (starts at the 1:35 mark) and Gates Foundation CEO Sue Desmond-Hellmann on how her foundation views public health and what the United States can learn from global efforts (starts at the 15:00 mark). MENTIONED ON THE SHOW Bijan's full 2016 appearance on "Pulse Check," where he explained how venture capitalists approach the health industry and how he decides where to invest. Sue's full 2017 appearance on "Pulse Check," where she explained her foundation's work on problems like polio and why she wishes "prevention" was more of a political priority in U.S. health efforts.

No child should die of measles in 2019. Or any disease that can be prevented by Vaccine or basic preventive care. That’s the view of Sue Desmond-Hellmann, CEO of the Bill and Melinda Gates Foundation, speaking to Edie lush on this Episode. Yet children still do die needlessly. Which shows the world still has work to do to continue to grow healthier. Progress over the last decades has been remarkable. The near abolition of measles is just one example.  A good part of the credit goes to two organizations, The Global Fund and Gavi, the vaccine alliance. Their work has helped people live longer healthier lives, particularly in the poorest places on earth. But now governments must decide whether to replenish their funds. Sue Desmond Hellman argues that it is the best investment in the future.

Dr. Sue Desmond-Hellmann is a physician, scientist and philanthropist who has devoted her career to improving the human condition. Trained as an oncologist, she spent 14 years at biotech firm Genentech, where she led the development of Avastin and Herceptin, two of the first gene-targeted therapies for cancer. Today, as CEO of the Bill & Melinda Gates Foundation, Dr. Desmond-Hellmann leads the organization's vision for a world where every person has the opportunity to live a healthy and productive life. In this episode, Dr. Sue Desmond-Hellmann shares her work as a pioneer in healthcare for more than 30 years, including her efforts to drive major developments toward the eradication of disease, poverty and inequity. For more information and full episode transcription go to Contagious Conversations (www.cdcfoundation.org/conversations). Key Takeaways: [1:03] The biggest influencers in Dr. Sue Desmond-Hellmann´s career. [2:50] How did Dr. Sue Desmond-Hellmann become the leader of one of the world largest health philanthropies? [5:26] Investing in human capital can translate into economic success. [6:23] The case of Ethiopia. [7:06] The most important value in public-private partnerships. [8:32] How a "volume guarantee" enhances philanthropy. [10:02] Encouraging companies to pay attention to where their future customers are going to be. [10:55] How does Dr. Desmond-Hellmann relax and recharge? [12:03] The importance of taking thoughtful risks in philanthropy. [13:11] Big bold collaborations can improve and save more lives. [16:02] What areas of global health is Dr. Hellmann most optimistic about? [16:50] HIV and malaria. [18:47] Tuberculosis today is one of the hardest diseases to tackle. [20:13] TB vaccine is closer than ever. [20:28] Dr. Desmond-Hellmann shares her thoughts about a nationalistic perspective. [22:30] What keeps her up at night? She worries about people getting the wrong information about vaccines. [24:50] Dr. Desmond-Hellmann’s biggest challenge at the Gates Foundation. [25:46] It is not easy to change systems. [27:04] Ethiopia works to change its health delivery system. [28:10] What's the biggest opportunity for the Gates Foundation? [28:57] It is possible for anyone around the world to make a difference. [29:20] Advice for women who want to become CEOs and innovators: Keep learning! [30:40] Ask for help. [31:23] Be willing to take risks. [32:39] Defining point in Dr. Desmond-Hellmann’s career: cancer-fighting breakthrough drug Herceptin.   Mentioned in This Episode: CDC Foundation Answer this episode’s question What is your favorite thing to do to recharge after a busy day? Email your answer to info@cdcfoundation.org to win some Contagious Conversations merchandise. For more information about this episode go to Contagious Conversations.

The CEO of the Bill and Melinda Gates Foundation talks about the battles we face today, and how she maintains optimism amid enormous challenges.

On this week’s Tech Nation, Moira speaks with Dr. Sue Desmond-Hellmann, the CEO of The Bill & Melinda Gates Foundation, and Dr. Penny Heaton, CEO of The Bill & Melinda Gates Medical Research Institute, also called Gates MRI. Then scientist-entrepreneur Dr. Jacob Glanville, co-founder and Chief Scientific Officer of Distributed Bio, talks about developing a universal flu vaccine.

The political fights over U.S. health policy often pale next to the world's health care challenges — and Sue Desmond-Hellmann would know. The doctor-turned-CEO of the Bill & Melinda Gates Foundation is on the front lines of the global public health battle, as her organization tackles challenges like eradicating polio and preventing maternal and newborn deaths. Sue caught up with POLITICO’s Dan Diamond last week to discuss if the Trump administration’s putting global progress at risk (starts at the 2:45 mark), the Gates Foundation’s work around the globe, the public health priorities that are being overlooked, and the role of philanthropy in solving the world’s crises. We’d appreciate your help: Please share PULSE CHECK and rate us on your favorite podcast app! Have questions, suggestions or feedback? Email ddiamond@politico.com.

Part two of the discussion between former Genentech and Facebook CFO David Ebersman and Venrock’s Bryan Roberts centers on Ebersman’s time at Genentech, where he started working in his 20s and worked up his way up, eventually becoming CFO. He shares anecdotes about working with another executive dynamic duo, Art Levinson and Sue Desmond-Hellmann, and what he learned about problem-solving after working closely with them for several years. Ebersman also discusses Roche’s hostile takeover of Genentech in 2009, and his perspective on financial modeling following the deal.   

Sue Desmond-Hellmann, CEO of the Bill & Melinda Gates Foundation, joins hosts Nick Ashburn and Sherryl Kuhlman to discuss her work with the Gates Foundation, their movement for positive change, and their cultural adoption of a 52 week parental plan on Dollars and Change. See acast.com/privacy for privacy and opt-out information.

Eric Topol talks with Sue Desmond-Hellmann about her multidimensional career and how to scale precision medicine for global public health.

Sue Desmond-Hellmann BBC5 Live Interview - May 20, 2015 by Gates Foundation